Non-interventional population-based prospective cohort study in multiple databases comparing patients with gout who initiate lesinurad in combination with an existing xanthine oxidase inhibitor (XOI) (lesinurad+XOI cohort) to a propensity score-matched cohort of similar patients from the same data source who continue treatment with XOI monotherapy (XOI mono cohort). Study will characterize the cardiovascular safety of lesinurad in combination with XOI in patients with gout aged 18+ years compared with similar patients who continue XOI monotherapy. Primary objective: to assess the relative incidence of major adverse cardiac events plus hospitalization for unstable angina (MACE+ events) in patients with gout in both cohorts. Secondary objectives: to describe the characteristics of the cohorts prior to matching; to assess the relative incidence of hospitalisation for acute kidney injury between the matched cohorts; to assess the relative incidence of individual MACE+ components in the matched cohorts.

Start Date29 Jan 2021

Sponsor / Collaborator

AstraZeneca PLC

NCT03272425

/ CompletedPhase 1

A Randomized, Open-label, Replicate, Crossover, 4-period Study to Assess the Bioequivalence of Lesinurad/Allopurinol Fixed-dose Combination 200/300 mg Tablets From Ardea Biosciences, Inc. (Test Drug) Versus Lesinurad, 200 mg Tablet From AstraZeneca (Comparator 1) Coadministered With Zyloric®, Allopurinol 300 mg Tablet From Aspen Pharma Industria Farmaceutica Ltda. (Comparator 2) in Healthy Female and Male Adult Subjects, Under Fasting Conditions.

To assess the bioequivalence between lesinurad/allopurinol 200/300 FDC tablets and coadministered lesinurad and allopurinol tablets in the fasted state based on the pharmacokinetic (PK) evaluation of lesinurad and allopurinol in healthy adult subjects.

Start Date14 Aug 2017

Sponsor / Collaborator

Ardea Biosciences, Inc.

NCT03226899

/ TerminatedPhase 4

A Phase 4, Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance (eCrCl) 30 to <60 mL/Min Who Have Not Achieved Target Serum Uric Acid Levels (sUA) on an XOI Alone

This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of serum urate (sUA).

Start Date19 Jul 2017

Sponsor / Collaborator

Ironwood Pharmaceuticals, Inc.

[+1]

100 Clinical Results associated with Lesinurad

100 Translational Medicine associated with Lesinurad

100 Patents (Medical) associated with Lesinurad

217

Literatures (Medical) associated with Lesinurad

01 Sep 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Development of a fluorescence-based assay for screening of urate transporter 1 inhibitors (II): Optimization of fluorescent substrates and structure-activity relationships analysis

Article

Author: Li, Jing ; Chen, Hongming ; Cai, Haojie ; Lu, Xiaodan ; Dai, Zhixi ; Zhang, Lei

Urate transporter 1 (URAT1) inhibitors represent a promising therapeutic approach for hyperuricemia and gout. A non-radioactive cell-based platform for screening URAT1 inhibitors using 6-carboxyfluorescein (6-CFL) was previously established by our team. In this study, aiming to optimize our testing platform, 10 potential fluorescent substrates were screened from the commercially available fluoresceins using molecular docking and pKa prediction. Among them, dibromofluorescein (DBF) and diiodofluorescein (DIF) were identified as specific transport substrates for UTAR1 with significant fluorescence changes in cellular uptake. DBF and DIF exhibited Km values similar to that of 6-CFL. Using DBF or DIF as substrates, the IC₅₀ values of the URAT1 inhibitors benzbromarone and lesinurad remained within the same order of magnitude as those obtained by 6-CFL. Notably, DBF enables visual detection, further extending the utility of this non-radioactive platform for in vitro screening of URAT1 inhibitors. Molecular dynamics (MD) simulations and free energy calculations were employed to compare the interactions and binding affinities of 6-CFL, DBF, and DIF with URAT1, respectively. Finally, structure-activity relationships (SARs) analysis was conducted to preliminarily identify substituents modulating the binding affinity of commercially available fluoresceins.

01 Jun 2025·JOURNAL OF MOLECULAR STRUCTURE

Design, synthesis and pharmacological evaluation of triazolopyrimidines derivatives as novel agonists for benzodiazepine receptor

Author: Li, Mengjiao ; Yi, Shijia ; Liu, Zheng ; Yan, Hui ; Hu, Lina ; Lei, Kang ; Wang, Xuekun ; Wang, Shiben

In this paper, two series of triazolopyrimidines derivatives were designed, synthesized, and all the target compounds were structurally confirmed using ¹H NMR, ¹³C NMR and HRMS methods.Pharmacol. experiments were carried out using maximal electroshock (MES), s.c. pentylenetetrazole (scPTZ) and rotating rod (ROT) models for activity and neurotoxicity screening, and potential compounds were screened out for further determination of ED₅₀, TD₅₀ and in vitro binding experimentsFinally, compound 5,7-Bis(pentyloxy)-[1,2,4]triazolo[1,5-a]pyrimidine (6b) with best activity and lowest toxicity was obtained.The pharmacol. results showed that the ED₅₀ of compound 6b was MES = 11.3 mg/kg, PTZ = 9.5 mg/kg, which was superior to that of the carbamazepine (MES = 6.3 mg/kg) and ethosuximide (PTZ = 3.6 mg/kg).The IC₅₀ of compound 6b binding affinity toward the GABA_A receptor was 0.15 μM, and the GABA content experiments showed that compound 6b significantly increased the GABA content in the rat brain.In elevated plus maze (EPM) assay, compound 6b possessed anxiolytic effects.In silico studies, most of the target compounds have suitable physicochem. and pharmacokinetic data with the possibility of drug-forming properties, mol. docking results showed that compound 6b could generate more interactions with the amino acid residues of diazepam active site of GABA_A receptor.

01 Apr 2025·SEMINARS IN ARTHRITIS AND RHEUMATISM

Are participants in gout medication registration clinical trials representative of people with gout in the general population?

Article

Author: Dalbeth, Nicola ; Gamble, Gregory D ; Liu, Jendy

BACKGROUND:

Ensuring clinical trial participants are representative of the target population is important for the generalizability of trial findings. This study aimed to determine if phase 3 clinical trials of gout medications approved by the US Food and Drug Administration (FDA) included participants representative of the US general population with gout.

METHODS:

Gout therapeutics were identified by searching the FDA and CenterWatch websites. Data from phase 3 clinical trials of FDA approved gout medications between 2009 and 2023 were analyzed. Demographic variables (sex, age, and ethnicity) and comorbidities (hypertension, myocardial infarction, heart failure, nephrolithiasis, chronic kidney disease, BMI ≥30 kg/m², and diabetes) were extracted and compared with published data from the 2007-2008 and 2015-2016 US National Health and Nutrition Examination Survey (NHANES). Data were pooled using a random effects model and presented as a percentage with a 95 % confidence interval.

RESULTS:

Twelve phase 3 clinical trials were included, covering febuxostat, colchicine, pegloticase, lesinurad, and canakinumab. Compared to the NHANES gout population, clinical trials over-represented men, younger individuals, and White ethnicity participants. Under-representation was observed for clinical trial participants with hypertension, prior myocardial infarction, nephrolithiasis, and diabetes, while those with a BMI ≥30 kg/m² were over-represented.

CONCLUSIONS:

FDA approved gout medication trials since 2009 have not enrolled a study population that is representative of the US general population with gout, particularly regarding age, ethnicity, and cardiometabolic comorbidities. For broader applicability, future phase 3 trials should ensure the greater inclusion of women, older individuals, diverse ethnicities, and those with common gout-associated comorbid conditions.

News (Medical) associated with Lesinurad

12 Jun 2024

·www.globenewswire.com

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointments of Barry Quart, Pharm.D., as Chief Executive Officer (CEO) and Director, David Szekeres as President, and Kleanthis G. Xanthopoulos, Ph.D., as the new Chair of the Board of Directors (Board). Dr. Xanthopoulos, currently the lead independent member of the Board since 2022, has been appointed Chair of the Board. Dr. Xanthopoulos succeeds Wubin (Bill) Pan, Ph.D., M.B.A., who will remain on the Board and serve as an advisor to the Company during the transition. “On behalf of the board and the Connect team I would like to thank Drs. Zheng Wei and Wubin (Bill) Pan, who co-founded Connect with the vision to bring next-generation therapeutics to patients with inflammatory diseases and improve their lives. We are grateful for their contributions and unwavering commitment to the Connect mission by building an outstanding organization with Phase 3-ready programs and a robust pipeline,” said Kleanthis G. Xanthopoulos, Ph.D., Chair of the Board of Directors of Connect. “The highly differentiated data generated from positive readouts in both asthma and atopic dermatitis for the lead asset, rademikibart, establishes Connect now as a U.S.-driven late-stage company entering its pre-commercial phase. I am thrilled to welcome the new leadership team with such an impressive track record and eager to leverage Barry’s and David’s operational expertise and wealth of experience to unlock the maximum potential/value of rademikibart and the rest of the pipeline.” "Founding and leading Connect with Bill and working with many talented colleagues who are passionate about discovery and development of life-changing medicines in the past 12 years has been a true honor and privilege," said Dr. Zheng Wei. "As Connect evolved to focus on advancing rademikibart, Bill and I look forward to supporting Barry and David as Connect enters an exciting new phase." Dr. Barry Quart, the Company’s newly appointed CEO, brings over 30 years of extensive experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. He has personally led several early-stage biotech companies through late-stage clinical development and regulatory strategy, highlighted by nine U.S. Food and Drug Administration (FDA) approved drugs. “I am honored to assume the CEO role for Connect and to join the Board. I am incredibly excited about the potential of the Company going forward with rademikibart, which I believe to be a best-in-class competitor to dupilumab,” said Barry Quart, Pharm.D., CEO and Director of Connect. “With the multiple innovative therapies in our pipeline, a cash runway into at least 2026, and an expanded management team with proven experience in the U.S., I believe we have all the elements in place to achieve significant shareholder returns in the future.” Dr. Quart was most recently CEO at Heron Therapeutics. He first served as CEO and Director starting in 2012, transitioned to President and CEO in 2019 and was named Chair of the Board in October 2020. At Heron, Dr. Quart oversaw the development and approval of four drugs: two drugs for CINV (CINVANTI® and SUSTOL®) and two acute care drugs (ZYNRELEF® and APONVIE®). Prior to Heron, Dr. Quart co-founded Ardea Biosciences, Inc. in 2006 and served as its President and Chief Executive Officer and Director from its inception through its acquisition by AstraZeneca PLC in 2012. At Ardea, Dr. Quart invented and oversaw the development of a drug for gout (ZURAMPIC®), as well as the design and development of a series of MEK inhibitors for cancer that were licensed to Bayer AG. Dr. Quart currently serves on the Board of Directors of Kiniksa Pharmaceuticals. He is an inventor on 18 U.S. patents and an author on 75 publications and abstracts. Dr. Quart received his Pharm.D. from the University of California, San Francisco. David Szekeres is an experienced life science executive with a proven track record of creating value with deep operational, commercial, corporate development/strategy, and legal expertise. Mr. Szekeres was most recently Executive Vice President and Chief Operating Officer of Heron Therapeutics. Prior to Heron, he was the Chief Business Officer and General Counsel of Regulus Therapeutics, a clinical-stage biotech company focused on RNA therapeutics and the Head of Mergers & Acquisitions at Life Technologies Corporation. Mr. Szekeres also holds positions as the Chair of the Board of GRI Bio, Inc. (Nasdaq: GRI) and is a member of the Board of Directors of CureMatch, Colossal Biosciences, and the Sanford Burnham Prebys Medical Discovery Institute. He received his J.D. from Duke University School of Law and earned his B.A. at the University of California, Irvine. About Connect Biopharma Holdings Limited Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). For more information, please visit: https://www.connectbiopharm.com/ Forward-Looking Statements Connect Biopharma cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may”, “could”, “will”, “would”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “intend”, “predict”, “seek”, “contemplate”, “look forward”, “potential”, “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company’s plans to advance the development of its product candidates, the timing of achieving any development, regulatory or commercial milestones or reporting data or whether such milestones or data will be achieved or generated, including whether any new drug application will be submitted or accepted and the timing thereof, and the potential of such product candidates, including to achieve any benefit, improvement, differentiation, trend or profile or any product approval or be effective, and the sufficiency of the Company’s cash and investments to support planned operations. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its plans will be achieved. Actual data may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on April 16, 2024, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Connect Biopharma undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included in Connect Biopharma’s filings with the SEC which are available from the SEC’s website (www.sec.gov) and on Connect Biopharma’s website (www.connectbiopharm.com) under the heading “Investors.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. INVESTOR CONTACT:Tim McCarthyLifeSci Advisorstim@lifesciadvisors.com

Executive ChangeAcquisition

01 Apr 2019

·www.biospace.com

Ironwood Pharma Spins off Cyclerion Therapeutics With 5 Orphan Disease Compounds

Today, Cyclerion has been launched on the second floor of a 200,000-square-foot , 3-story space on Binney Street, in Cambridge. In late-February, Cambridge, Mass.-based Ironwood Pharmaceuticals announced it had entered into a private placement deal of up to $175 million that would be used to support its spinoff of Cyclerion Therapeutics. Today, Cyclerion has been launched on the second floor of a 200,000-square-foot, 3-story space on Binney Street, in Cambridge. After the separation, no ongoing funding between Ironwood and Cyclerion is expected aside from some shorter-term transition expenses and other services. Ironwood isn’t expected to retain equity in the new company and did not invest in the private placement. Cyclerion plans to utilize the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. It has a portfolio of five differentiated sGC stimulator programs each designed for unique target tissues. These programs all have milestones expected this year. They include olinciguat in Phase II development for sickle cell disease, praliciquat in Phase II for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. IW-6463 is in Phase I for serious and orphan central nervous system diseases, and two late-stage discovery programs target serious liver and lung diseases. At the time of the private placement, Peter Hecht, Ironwood’s then chief executive officer and expected chief executive of Cyclerion, stated, “We are grateful for the strong support from the outstanding and experienced group of investors who are participating in this financing. We look forward to launching Cyclerion and Ironwood less than one year since our initial announcement of the separation, and to advancing our efforts to create innovative new medicines for patients and generate value for our shareholders.” Ironwood was founded in 1998 and developed Linzess to treat irritable bowel syndrome with constipation, which launched commercially in 2012 with Allergan. Ironwood has two experimental compounds in mid- and late-stage clinical trials for gastrointestinal disorders. Mark Mallon, who recently took over as Ironwood’s chief executive officer after 24 years at AstraZeneca, told the Boston Globe , “These two companies are particularly well-positioned, post the spin[off], to really do great things. It was the right strategy at the right time.” As part of the tax-free spinoff, today Ironwood shareholders will receive one share of Cyclerion stock for every 10 shares of Ironwood stock. Cyclerion also begins trading on the Nasdaq Tuesday. David Nierengarten, an analyst for Wedbush Securities, wrote in a note that the spinoff was a “reasonable strategy” that leverages the two executives’ strengths. In the case of Hecht, research and development; in the case of Mallon, marketing gastrointestinal franchises. Per the Boston Globe , “Ironwood announced it would split into two independent publicly traded firms last May, three weeks after it took the unusual step of telling shareholders that an activist investor, Alex Denner, was seeking to join its board.” Denner is the chief investment officer of a Greenwich, Conn.-based hedge fund, Sarissa Capital Management. Prior to launching Sarissa in 2012, Denner ran biotech investments for Carl Icahn. In interviews with the Boston Globe last spring, Denner indicated he wasn’t pleased with Ironwood’s stock price and didn’t like the way the company launched drugs for common diseases like irritable bowel disease while also developing drugs for rare diseases. He did, however, endorse the spinoff. Hecht, on his part, indicates he had been discussing the idea of splitting up the company for several years and that Denner was “not a key protagonist in the story.” He instead, gives credit to other investors. The spinoff also marks a much smaller company for Ironwood. At year-end 2017, Ironwood had 730 staffers, but under its new identity, will have 330. About 140 moved to Cyclerion and about 260 jobs were eliminated in January 2018. Most of those job cuts came from a decision to stop marketing lesinurad, a drug for gout it had licensed from AstraZeneca in 2016. Sales were disappointing.

Phase 2AcquisitionPhase 1

08 Jun 2018

·www.biospace.com

Ironwood Pharma’s Sickle Cell Drug Gets Orphan Drug Designation

Ironwood Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced the U.S. Food and Drug Administration (FDA) had granted its olinciguat (IW-1701) Orphan Drug Designation for sickle cell disease. Ironwood Pharmaceuticals , headquartered in Cambridge, Massachusetts, announced the U.S. Food and Drug Administration (FDA) had granted its olinciguat (IW-1701) Orphan Drug Designation for sickle cell disease. The FDA’s Office of Orphan Drug Products grants orphan status to drugs designed to treat diseases that affect fewer than 200,000 people in the U.S. It offers several benefits, including seven years of market exclusively after FDA approval, prescription drug user fee waivers and tax credits for qualified clinical trials. Olinciguat is an oral soluble guanlylate cyclase (sGC) stimulator. The company is currently enrolling patients in its Phase II STRONG-SCD clinical trial. The company expects to enroll about 80 patients in the trial, which will evaluate the safety, tolerability, pharmaocokinetics and pharmacodynamics of the drug in sickle cell disease patients. “There is an urgent need for new, innovative treatments for patients with sickle cell disease, a debilitating and potentially fatal inherited blood disorder that causes painful crises, organ damage and other serious complications,” said Christopher Wright, Ironwood’s senior vice president of global development and chief development officer, in a statement. “The orphan drug designation adds momentum to our clinical program investigating olinciguat, which has the potential to improve multiple aspects of sickle cell disease pathophysiology. The designation is also an important milestone in Ironwood’s evolution as we advance our pipeline of SGC stimulators focused on the treatment of serious and orphan diseases.” In early May, Ironwood announced it will split into two independent companies. They will be Ironwood and what was being called R&D Co, although presumably a more appropriate name will be chosen. The idea is to separate its sGC business from its commercial and gastrointestinal business. The split is expected to be finished in the first half of next year, and is designed to “unlock value, increase operational performance and strategic flexibility, and tailor capital structure for each business.” When announced, company shareholders were not enthusiastic. Shares dropped more than 3 percent in early trading and as much in premarket trading as 6 percent. Ironwood indicated it believes the separation would lead to it becoming profitable. It plans to build on its commercial success to accelerate the growth of its in-market product while advancing development programs for gastrointestinal disease, uncontrolled gout, and abdominal pain. The R&D company will focus on the sGC pipeline, which includes olinciguat. The other compound in this pipeline includes its Phase II praliciguat being developed for cardiovascular disorders, diabetic nephropathies, heart failure, and hypertension in diabetes. In a statement at the time, Peter Hecht, the company’s chief executive officer, said, “Since our founding 20 years ago, we have been driven by a simple mission: create and commercialize innovative drugs that can change patients’ lives and generate value for our shareholders. Ironwood today markets three commercial medicines, including Linzess, a category leader, and is advancing a deep pipeline of drug candidates targeting severe and high unmet need diseases.” Linzess and Constella are prescribed to treat adults with irritable bowel syndrome (IBS) with constipation, and Duzallo and Zurampic are prescribed to treat gout. It also has IW-3718, being developed for persistent gastroesophageal reflux disease (GERD), with Phase III trials expected to start in this year’s third quarter. It also has linaclotide delayed release, which is being tested to treat abdominal pain associated with all forms of IBS.

Phase 2Orphan DrugPhase 3

100 Deals associated with Lesinurad

External Link

KEGG	Wiki	ATC	Drug Bank
D09921	Lesinurad	M04AB05	DB11560

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gout	United States	Ironwood Pharmaceuticals, Inc.	22 Dec 2015
Hyperuricemia	United States	Ironwood Pharmaceuticals, Inc.	22 Dec 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic tophaceous gout	Phase 3	United States	Ardea Biosciences, Inc.	01 Jan 2012
Chronic tophaceous gout	Phase 3	Australia	Ardea Biosciences, Inc.	01 Jan 2012
Chronic tophaceous gout	Phase 3	Canada	Ardea Biosciences, Inc.	01 Jan 2012
Chronic tophaceous gout	Phase 3	New Zealand	Ardea Biosciences, Inc.	01 Jan 2012
Chronic tophaceous gout	Phase 3	Poland	Ardea Biosciences, Inc.	01 Jan 2012
Chronic tophaceous gout	Phase 3	Switzerland	Ardea Biosciences, Inc.	01 Jan 2012
Primary gout	Phase 3	United States	Ardea Biosciences, Inc.	01 Dec 2011
Primary gout	Phase 3	Australia	Ardea Biosciences, Inc.	01 Dec 2011
Primary gout	Phase 3	Belgium	Ardea Biosciences, Inc.	01 Dec 2011
Primary gout	Phase 3	Canada	Ardea Biosciences, Inc.	01 Dec 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03226899 (CTgov)	Phase 4	Gout \| Chronic Kidney Diseases	242	Placebo+XOI+colchicine (Placebo + XOI)	upeyzoetoy = wrfinbgxgs elqmpaoogo (sxesheamri, aqpcsfgsmw - unlezzbybj) View more	-	04 Nov 2021
				corticosteroids+Lesinurad+XOI+colchicine (Lesinurad + XOI)	upeyzoetoy = yzeidtavkk elqmpaoogo (sxesheamri, pdzwranlyr - ibowzkayuc) View more
NCT01510769 (CRYSTAL extension, Pubmed \| Arthritis Res Ther)	Phase 3	Chronic tophaceous gout	235	Lesinurad plus Febuxostat	xbmzetwods(wlpmxtptwr) = aaobhitroc rhpzvwmrce (xgewccwigx )	-	07 Jan 2019
NCT01808144 (CRYSTAL, CTgov)	Phase 3	Gout	196	lesinurad+febuxostat (Lesinurad 400 mg + Febuxostat 80 mg)	dczmlmajxr = izilqdltuv dzkbummkmc (jbjkkfagyh, gqhhxtqloo - gpbdxuhczc) View more	-	30 Jan 2018
				lesinurad+febuxostat (Lesinurad 200 mg + Febuxostat 80 mg)	dczmlmajxr = saqfvkxnyq dzkbummkmc (jbjkkfagyh, uzvdthnutl - ihywkpszmx) View more
NCT01508702 (Pubmed \| Rheumatology (Oxford)) Manual	Phase 3	Gout	214	Lesinurad	yaahiprctr(jqzgozbjga) = wtehencccl qqokfwejtr (lrcuektfuu ) View more	Positive	01 Dec 2017
				Placebo	yaahiprctr(jqzgozbjga) = zwjetnbrja qqokfwejtr (lrcuektfuu ) View more
NCT01510769 (Pubmed \| Arthritis Rheumatol)	Phase 3	Chronic tophaceous gout	324	Lesinurad 200 mg	fbglhvlyhb(cholgtgcjs) = erwqidptpx vadsxzujxp (fowklaeyge ) View more	Positive	01 Sep 2017
				Lesinurad 400 mg	fbglhvlyhb(cholgtgcjs) = zsnodgfyfm vadsxzujxp (fowklaeyge ) View more
NCT01493531 (CLEAR 2, Pubmed \| Ann Rheum Dis)	Phase 3	Gout serum uric acid (sUA)	610	Lesinurad 200 mg + Allopurinol	yfodcckqdq(tjxhctesdw) = yvoxmwcmwv wfaqseupxt (inlzkaqszg )	-	01 May 2017
				Lesinurad 400 mg + Allopurinol	yfodcckqdq(tjxhctesdw) = idoiyxozvh wfaqseupxt (inlzkaqszg )
NCT01808131 (CLEAR 1 & 2, ACR2016)	Phase 3	Gout serum uric acid (sUA)	-	Lesinurad 200 mg + Allopurinol	ahixluxqof(kjfirhtrbs) = EAIRs of kidney stone TEAEs were 0.5 and 2.0 for LESU200 and LESU400, respectively osqlhcwwxy (funlvemfla ) View more	Positive	13 Nov 2016
				Lesinurad 400 mg + Allopurinol
NCT01510158 (CLEAR 1, CTgov)	Phase 3	Gout \| Primary gout	607	Lesinurad+Allopurinol (Lesinurad 200 mg + Allopurinol)	jedtwwwmuw = vigwlgdhti lllwkofffc (cxraepealh, nrsezbbkyk - lbuhafpoel) View more	-	18 Aug 2016
				Lesinurad+Allopurinol (Lesinurad 400 mg + Allopurinol)	jedtwwwmuw = rmdkjhvwxt lllwkofffc (cxraepealh, cknzakimaa - lgpfqivkln) View more
EULAR2016	Phase 3	Gout	-	Lesinurad 200 mg + Allopurinol	cpatqgxlwf(kmlgadaztp) = iigcqjibmg efdmkfkcuu (jzclcoogok )	-	08 Jun 2016
				Lesinurad 400 mg + Allopurinol	cpatqgxlwf(kmlgadaztp) = ldvpcjggog efdmkfkcuu (jzclcoogok )
NCT01808131 (CLEAR 1 and 2, EULAR2016)	Phase 3	Gout serum uric acid (SUA)	-	Lesinurad 200 mg + Allopurinol	ntxdnsbjps(uwgmoomfwn) = EAIRs (per 100-PY) of TEAEs and serious TEAEs at any time during core or extension studies were 54.2 and 5.8 for LESU200 and 57.2 and 8.3 for LESU400. eitcgyxvfx (tlhaquiqfx ) View more	Positive	08 Jun 2016
				Lesinurad 400 mg + Allopurinol

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis